Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
posted on 2022-06-15, 06:32authored byE Lopci, RJ Hicks, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, RD Seban, C Sachpekidis, O Humbert, O Gheysens, AWJM Glaudemans, W Weber, RL Wahl, Andrew ScottAndrew Scott, N Pandit-Taskar, N Aide
<p>Purpose: The goal of this guideline/procedure standard is to assist nuclear medicine physicians, other nuclear medicine professionals, oncologists or other medical specialists for recommended use of [18F]FDG PET/CT in oncological patients undergoing immunotherapy, with special focus on response assessment in solid tumors. Methods: In a cooperative effort between the EANM, the SNMMI and the ANZSNM, clinical indications, recommended imaging procedures and reporting standards have been agreed upon and summarized in this joint guideline/procedure standard. Conclusions: The field of immuno-oncology is rapidly evolving, and this guideline/procedure standard should not be seen as definitive, but rather as a guidance document standardizing the use and interpretation of [18F]FDG PET/CT during immunotherapy. Local variations to this guideline should be taken into consideration. </p>
Funding
The support for the open-access publication of the current manuscript was provided by the IRCCS -Humanitas Research Hospital, Rozzano (MI), Italy.
History
Publication Date
2022-06-01
Journal
European Journal of Nuclear Medicine and Molecular Imaging